Dr. Frank Hollinger is the Vice President of Corporate Operations for the Americas (Canada, USA, South America) for Douglas Connect. Dr. Frank Hollinger began applying synthetic chemistry, computational chemistry, chemoinformatics and information technology to solving drug discovery and development challenges in major pharmaceutical companies. After eight years he ventured into the entrepreneurial world of start-up biotechs where he honed the application of sound business principles to cutting edge science and technology. This led him to co-found an international pharmaceutical company Sphaera Pharma which spun-off several companies and brought several drugs safely into clinical trials. For more than 20 years he has led collaborative interdisciplinary teams of scientists, developers, and information scientists to take on and solve the challenges of taking a drug from conception to patients. He brings his diverse background and experience to Douglas Connect with an eye toward developing and fostering relationships with trusted partners to enable them to solve their challenges and achieve their vision of success. Dr. Hollinger obtained his PhD in organic and computational chemistry from Columbia University under the direction of Prof. W. Clark Still. He is the author, co-author, or co-inventor of more than 50 articles in peer reviewed journals, patents, and invited presentations.
Watch Webinar
Dr. Frank Hollinger is the Vice President of Corporate Operations for the Americas (Canada, USA, South America) for Douglas Connect. Dr. Frank Hollinger began applying synthetic chemistry, computational chemistry, chemoinformatics and information technology to solving drug discovery and development challenges in major pharmaceutical companies. After eight years he ventured into the entrepreneurial world of start-up biotechs where he honed the application of sound business principles to cutting edge science and technology. This led him to co-found an international pharmaceutical company Sphaera Pharma which spun-off several companies and brought several drugs safely into clinical trials. For more than 20 years he has led collaborative interdisciplinary teams of scientists, developers, and information scientists to take on and solve the challenges of taking a drug from conception to patients. He brings his diverse background and experience to Douglas Connect with an eye toward developing and fostering relationships with trusted partners to enable them to solve their challenges and achieve their vision of success. Dr. Hollinger obtained his PhD in organic and computational chemistry from Columbia University under the direction of Prof. W. Clark Still. He is the author, co-author, or co-inventor of more than 50 articles in peer reviewed journals, patents, and invited presentations.